Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis-Reference-Cited by-同舟云学术

Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis

Published:2021-01-20 Issue:4 Volume:30 Page:482-491
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Morales Daniel R.¹²^ORCID,Macfarlane Tatiana¹,MacDonald Thomas M.¹^ORCID,Hallas Jesper²^ORCID,Ernst Martin Thomsen²,Herings Ron M. C.³,Smits Elisabeth³,Overbeek Jetty A.³,Mitchell Lyn¹,Morant Steven¹,Mackenzie Isla¹,Doney Alexander S. F.¹,Robertson Chris⁴,Bennie Marion⁵,Wei Li⁶,Nicholson Lizzie⁷,Morris Carole⁷,Flynn Robert W. F.¹

Affiliation:

1. MEMO Research, University of Dundee Dundee UK

2. Department of Clinical Pharmacology and Pharmacy University of Southern Denmark Odense Denmark

3. PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands

4. Department of Mathematics and Statistics University of Strathclyde Glasgow UK

5. Strathclyde Onstitute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow UK

6. School of Pharmacy University College London London UK

7. Electronic Data Research and Innovation Service NHS National Services Scotland Edinburgh UK

Funder

European Medicines Agency

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5191

Reference29 articles.

1. European Medicines Agency. PRAC recommends new measures to minimise known heart risks of hydroxyzine‐containing medicines. Available at:https://www.ema.europa.eu/en/news/prac‐recommends‐new‐measures‐minimise‐known‐heart‐risks‐hydroxyzine‐containing‐medicinesAccessed 19/09/2019.

2. Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

3. Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations

4. Data Resource Profile: Clinical Practice Research Datalink (CPRD)

5. Data Resource Profile: The Scottish National Prescribing Information System (PIS)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unintended impact of pharmacovigilance regulatory interventions: A systematic review;British Journal of Clinical Pharmacology;2023-08-28

2. Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study;Drug Safety;2022-04-19

3. Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis;Pharmacoepidemiology and Drug Safety;2021-01-20

4. Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases;The Functional Roles of Histamine Receptors;2021